AR117719A1 - Formulaciones orales de branaplam - Google Patents

Formulaciones orales de branaplam

Info

Publication number
AR117719A1
AR117719A1 ARP190103731A ARP190103731A AR117719A1 AR 117719 A1 AR117719 A1 AR 117719A1 AR P190103731 A ARP190103731 A AR P190103731A AR P190103731 A ARP190103731 A AR P190103731A AR 117719 A1 AR117719 A1 AR 117719A1
Authority
AR
Argentina
Prior art keywords
branaplam
oral formulations
tetramethylpiperidin
pyridazin
pyrazol
Prior art date
Application number
ARP190103731A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR117719A1 publication Critical patent/AR117719A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

La presente se refiere a composiciones farmacéuticas adecuadas para administración oral que comprenden 5-(1H-pirazol-4-il)-2-(6-((2,2,6,6-tetrametilpiperidin-4-il)oxi)piridazin-3-il)fenol (branaplam) y una ciclodextrina farmacéuticamente aceptable.
ARP190103731A 2018-12-21 2019-12-18 Formulaciones orales de branaplam AR117719A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN201811048667 2018-12-21

Publications (1)

Publication Number Publication Date
AR117719A1 true AR117719A1 (es) 2021-08-25

Family

ID=69165436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103731A AR117719A1 (es) 2018-12-21 2019-12-18 Formulaciones orales de branaplam

Country Status (14)

Country Link
US (1) US20220071996A1 (es)
EP (1) EP3897576A1 (es)
JP (1) JP2022513976A (es)
KR (1) KR20210107038A (es)
CN (1) CN113226285A (es)
AR (1) AR117719A1 (es)
AU (1) AU2019404930A1 (es)
BR (1) BR112021011744A2 (es)
CA (1) CA3119084A1 (es)
CL (1) CL2021001621A1 (es)
IL (1) IL283593A (es)
MX (1) MX2021007485A (es)
TW (1) TW202038908A (es)
WO (1) WO2020128915A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202304446A (zh) * 2021-03-29 2023-02-01 瑞士商諾華公司 剪接調節子用於減慢杭丁頓氏舞蹈症進展的治療之用途
WO2024015518A1 (en) * 2022-07-13 2024-01-18 Inaya Therapeutics, Inc. Inhalable imatinib formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions

Also Published As

Publication number Publication date
WO2020128915A1 (en) 2020-06-25
CN113226285A (zh) 2021-08-06
TW202038908A (zh) 2020-11-01
IL283593A (en) 2021-07-29
CA3119084A1 (en) 2020-06-25
BR112021011744A2 (pt) 2021-08-31
KR20210107038A (ko) 2021-08-31
CL2021001621A1 (es) 2022-02-11
MX2021007485A (es) 2021-08-05
JP2022513976A (ja) 2022-02-09
EP3897576A1 (en) 2021-10-27
AU2019404930A1 (en) 2021-06-03
US20220071996A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
CO2019001895A2 (es) Formulación novedosa para administración por vía oral
NI201100158A (es) Formulaciones de 4 - amino - 2 - (2, 6 - dioxopiperidina - 3 - il) isoindolina - 1, 3 - diona
ECSP10010224A (es) Formulaciones líquidas de hormona luteinizante (lh).
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
CL2021001621A1 (es) Formulaciones orales de branaplam
NI201600048A (es) Formulaciones de (s)- 3- (4-((4-(morfolinometil) bencil)oxi)-1-oxoisoindolin-2-il) piperidin-2, 6-diona
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
CY1117237T1 (el) Συνθεσεις σταθερων τιακουμυκινων
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
ECSP13012912A (es) Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
BR112022007207A2 (pt) Composição farmacêutica que compreende selexipag
EA201991287A1 (ru) Твердые фармацевтические композиции на основе тикагрелора для перорального применения
AR108233A1 (es) Composiciones farmacéuticas orales de nicotinamida
ECSP18000689A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones
AR033596A1 (es) Composicion farmaceutica para inyeccion intramuscular que contiene loxoprofeno
DOP2018000024A (es) Composiciones farmacéuticas sólidas para el tratamiento del vhc